by Truveta staff | Nov 16, 2023 | Research
In the world of healthcare, few conditions have seen as much transformation over the past decade as diabetes. With 37.3 million Americans living with diabetes, and a further 96 million in the prediabetes stage, it’s a life-altering health concern for nearly 40% of the...
by Truveta Research | Nov 10, 2023 | Research, Research Insights
Adequate treatments are a crucial piece in the fight against the spread of HIV, because they can make HIV viral load undetectable in the blood and thus untransmittable. Approved by the US Food and Drug Administration (FDA) in January 2021, one of the newest treatments...
by Truveta Research | Nov 10, 2023 | Research, Research Insights
Lecanemab received accelerated FDA approval in January 2023 and full FDA approval in July 2023. A potential side effect of the drug is brain swelling and/or small hemorrhages and is most common for people with the APOE ε4 genetic variant, therefore rates of APOE e4...
by Truveta Research | Nov 2, 2023 | Research, Research Insights
Adalimumab (Humira) and etanercept (Enbrel) are high-cost specialty medications used to treat a variety of autoimmune diseases. Medication adherence is often influenced by social drivers of health, so we aimed to measure adherence using the proportion of days covered...
by Truveta staff | Oct 26, 2023 | Research
Hidden under the surface of daily life, a disease often referred to as a “silent killer” is slowly taking hold over millions of Americans. While approximately 4.5M US adults have received a diagnosis of liver disease, a far larger yet largely unaware group is treading...
by Truveta staff | Oct 24, 2023 | Research
Each year, approximately 900,000 patients in the United States are affected by PE, a blood clot causing a blockage in one or more pulmonary arteries in the lungs and a leading cause of in-hospital death in the U.S. Acute pulmonary embolism (PE) is the third-leading...
